Fluphenazine plasma levels, dosage, efficacy, and side effects

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Therapeutics

Background:

• Acute exacerbations of schizophrenia require effective pharmacological interventions.
• Fluphenazine is an antipsychotic medication used in schizophrenia treatment.
• Understanding the relationship between fluphenazine dosage, plasma levels, and clinical response is crucial.

Purpose of the Study:

• To investigate if fluphenazine dose or plasma concentration predicts clinical improvement in acute schizophrenia.
• To determine if dose or plasma level predicts the occurrence or severity of side effects.

Main Methods:

• A 4-week, randomized, double-blind study involving 72 inpatients with acute schizophrenic exacerbations.
• Patients received oral fluphenazine at fixed doses of 10, 20, or 30 mg/day.
• Outcome measures included symptom improvement (positive and negative symptoms) and extrapyramidal symptom severity.

Main Results:

• Forty-two patients met the response criteria (≥40% improvement in positive symptoms).
• Fluphenazine plasma levels and dose predicted positive symptom improvement specifically within the responder group.
• Higher plasma levels were associated with increased akathisia and more severe extrapyramidal symptoms.

Conclusions:

• Optimal clinical improvement in responders was observed at fluphenazine plasma levels >1.0 ng/ml and doses >0.20-0.25 mg/kg/day.
• Plasma level monitoring may be beneficial for optimizing acute and maintenance treatment of schizophrenia.
• The study discusses the utility of a "responder-only" analysis strategy for future research.